Pharmaceutical Preparations · DE · CIK 1434868
Esperion develops and commercializes non-statin medicines for patients at risk for cardiovascular disease and elevated LDL-C
Comparable business profile · signals at a glance
In the 90 days to Mar 17, 2026: 3 sold $335K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 17, 2026 | Koenig Sheldon L.President and CEO | Sell | 25,578 | $2.72 | $70K |
| Mar 17, 2026 | Halladay BenjaminChief Financial Officer | Sell | 6,424 | $2.71 | $17K |
| Mar 17, 2026 | Looker BenjaminChief Legal Officer | Sell | 5,708 | $2.70 | $15K |
| Jan 20, 2026 | Looker BenjaminGeneral Counsel | Sell | 1,689 | $2.88 | $5K |
| Dec 17, 2025 | Koenig Sheldon L.President and CEO | Sell | 48,244 | $3.67 | $177K |
| Dec 17, 2025 | Halladay BenjaminChief Financial Officer | Sell | 7,337 | $3.67 | $27K |
| Dec 17, 2025 | Looker BenjaminGeneral Counsel | Sell | 6,517 | $3.67 | $24K |
| Oct 17, 2025 | Looker BenjaminGeneral Counsel | Sell | 1,248 | $2.62 | $3K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.